Targeted Oncology· @TargetedOnc · X·· 14 小时前评分70
正文 · 原文
Impressive Phase III INTerpath-001 data at #ESMO26!
Personalized mRNA vaccine + pembrolizumab in resected melanoma:
2-year RFS: 82.2% vs 70% (HR 0.58)
DMFS: 88.5% vs 80.2% (HR 0.62)
An important advance. Will this translate into more cures?
115 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Targeted Oncology · x.com